Corvus Pharmaceuticals stock
CRVSNASDAQCorvus Pharmaceuticals, Inc., HealthcareISIN US2210151005
37Score 37 out of 100, Weak
Price and trend
41 / 100
Price history
+30% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 24% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 58% below its 52-week high. Largest decline in 11 years: 97% (March 2017 to March 2023).
Chart figures for advanced users
- SMA 50$11.26
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.50
- The lowest closing price of the last twelve months.
- Resistance$25.52
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Corvus Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $982.22M, is number 188 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 37 out of 100 (Weak): rank 576 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $56.75M, financial debt $937K.Stability 69
Weaknesses
- DilutionShare count up 168% since 2020.Capital allocation 18
- Volatile share priceVolatility 179% a year over the last 12 months.Stability 69
- Loss-makingLoss of $15.28M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 38 to 37.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 11 Mar 2027in 118 days
- Last reported
- 5 Nov 2026EPS reported −$0.22 (expected −$0.19)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 12.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.81−7.9%
- Revenue
- $1.18M0.0%
- Earnings per share
- −$1.05−12.6%
- Revenue
- $1.26M−66.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.1%Cash is expected to fund operations into the second quarter of 2028 and trials are on track; no change visible.
“Based on our cash position at June 30, 2026, and our current plans, we expect our cash to fund operations into the second quarter of 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $333,689 in total.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Corvus Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- VerastemVSTM $1.06B40
- Solid BiosciencesSLDB $1.06B39
- Vor BiopharmaVOR $1.05B47
- Jade BiosciencesJBIO $1.01B42
- ImmaticsIMTX $975.63M28
- Odyssey TherapeuticsODTX $966.16M44
- PhilogenPHIL.MI $948.15M68
- Monte Rosa TherapeuticsGLUE $947.69M32
ETFs that hold Corvus Pharmaceuticals
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.05% | 0.35% | €1.25B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
Show 5 more
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.01% | 0.39% | €190.04M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.54B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.